REPORT: State of China Life Science - 2020 H1

Download this new exclusive ChinaBio® report with in-depth analysis of investment and partnering activity in China for 2020 H1 to discover the factors driving China life science investment. Learn how VC, IPO, and Partnering have rebounded despite COVID-19, but how M&A continues to slump. Read the latest analysis of life science investment activity to get ahead for ChinaBio® Partnering Forum Digital, August 25-27!

Report Details:

• New VC/PE funds rebound to 2018 levels

• Drug company investments back on top

• M&A deal values set to plummet 60%

• IPO funds raised could set another record at $11B

• New record for partnering on the way to $29B, up 65%